Pharmacologic targets for atrial fibrillation

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Despite advances in treatment, atrial fibrillation (AF) remains the most common arrhythmia in humans. Antiarrhythmic drug therapy continues to be a cornerstone of AF treatment, even in light of emerging non-pharmacologic therapies. Conventional antiarrhythmic drugs target cardiac ion channels and are often associated with modest AF suppression and the risk of ventricular proarrhythmia. Ongoing drug development has focused on targeting atrial-specific ion channels as well as novel non-ionic targets. Targeting non-ionic mechanisms may also provide new drugs directed towards the underlying mechanisms responsible for AF and possibly greater antiarrhythmic potency. Agents that act against these new targets may offer improved safety and efficacy in AF treatment.

Original languageEnglish
Pages (from-to)1161-1178
Number of pages18
JournalExpert Opinion on Therapeutic Targets
Volume11
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

Anti-Arrhythmia Agents
Ion Channels
Atrial Fibrillation
Drug therapy
Pharmaceutical Preparations
Therapeutics
Cardiac Arrhythmias
Safety
Drug Therapy

Keywords

  • Antiarrhythmic agent
  • Atrial fibrillation
  • Drug therapy
  • Mechanism
  • Pharmacotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Pharmacologic targets for atrial fibrillation. / Bhakta, Deepak; Miller, John.

In: Expert Opinion on Therapeutic Targets, Vol. 11, No. 9, 09.2007, p. 1161-1178.

Research output: Contribution to journalArticle

@article{17f83a44ee60407bbd14643892f4657d,
title = "Pharmacologic targets for atrial fibrillation",
abstract = "Despite advances in treatment, atrial fibrillation (AF) remains the most common arrhythmia in humans. Antiarrhythmic drug therapy continues to be a cornerstone of AF treatment, even in light of emerging non-pharmacologic therapies. Conventional antiarrhythmic drugs target cardiac ion channels and are often associated with modest AF suppression and the risk of ventricular proarrhythmia. Ongoing drug development has focused on targeting atrial-specific ion channels as well as novel non-ionic targets. Targeting non-ionic mechanisms may also provide new drugs directed towards the underlying mechanisms responsible for AF and possibly greater antiarrhythmic potency. Agents that act against these new targets may offer improved safety and efficacy in AF treatment.",
keywords = "Antiarrhythmic agent, Atrial fibrillation, Drug therapy, Mechanism, Pharmacotherapy",
author = "Deepak Bhakta and John Miller",
year = "2007",
month = "9",
doi = "10.1517/14728222.11.9.1161",
language = "English",
volume = "11",
pages = "1161--1178",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Pharmacologic targets for atrial fibrillation

AU - Bhakta, Deepak

AU - Miller, John

PY - 2007/9

Y1 - 2007/9

N2 - Despite advances in treatment, atrial fibrillation (AF) remains the most common arrhythmia in humans. Antiarrhythmic drug therapy continues to be a cornerstone of AF treatment, even in light of emerging non-pharmacologic therapies. Conventional antiarrhythmic drugs target cardiac ion channels and are often associated with modest AF suppression and the risk of ventricular proarrhythmia. Ongoing drug development has focused on targeting atrial-specific ion channels as well as novel non-ionic targets. Targeting non-ionic mechanisms may also provide new drugs directed towards the underlying mechanisms responsible for AF and possibly greater antiarrhythmic potency. Agents that act against these new targets may offer improved safety and efficacy in AF treatment.

AB - Despite advances in treatment, atrial fibrillation (AF) remains the most common arrhythmia in humans. Antiarrhythmic drug therapy continues to be a cornerstone of AF treatment, even in light of emerging non-pharmacologic therapies. Conventional antiarrhythmic drugs target cardiac ion channels and are often associated with modest AF suppression and the risk of ventricular proarrhythmia. Ongoing drug development has focused on targeting atrial-specific ion channels as well as novel non-ionic targets. Targeting non-ionic mechanisms may also provide new drugs directed towards the underlying mechanisms responsible for AF and possibly greater antiarrhythmic potency. Agents that act against these new targets may offer improved safety and efficacy in AF treatment.

KW - Antiarrhythmic agent

KW - Atrial fibrillation

KW - Drug therapy

KW - Mechanism

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=34548817300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548817300&partnerID=8YFLogxK

U2 - 10.1517/14728222.11.9.1161

DO - 10.1517/14728222.11.9.1161

M3 - Article

C2 - 17845143

AN - SCOPUS:34548817300

VL - 11

SP - 1161

EP - 1178

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 9

ER -